Phase II randomized study of preradiation treatment with temozolomide (TMZ) and bevacizumab (BEV) previous to TMZ plus radiation plus BEV versus the same treatment without BEV therapy in unresectable glioblastoma (GB): GENOM 009.

Carmen Balaña,Oscar Gallego,J.M. Viéitez,R. de las Peñas,Ana Herrero,Sergi Peralta,R Luque,M Gil,Salvador Villà,O. Etxaniz,Cristina Carrato,J Sepúlveda,Grupo Español de Investigación en Neuroncología

Phase II randomized study of preradiation treatment with temozolomide (TMZ) and bevacizumab (BEV) previous to TMZ plus radiation plus BEV versus the same treatment without BEV therapy in unresectable glioblastoma (GB): GENOM 009.

2011

Carmen Balaña
Oscar Gallego
J.M. Viéitez
R. de las Peñas
Ana Herrero
Sergi Peralta
R Luque
M Gil
Salvador Villà
O. Etxaniz
Cristina Carrato
J Sepúlveda
Grupo Español de Investigación en Neuroncología

e12519 Background: Unressectable GB hardly benefits from standard treatment. Patients frequently deteriorate neurologically during radiotherapy. An effective pre-radiation treatment might improve t...

Keywords:

Bevacizumab
Randomized controlled trial
Physical therapy
Glioblastoma
Temozolomide
Radiation
Cancer research
Medicine
Internal medicine
Pathology
Radiation therapy
Oncology
Standard treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations